The influence of multiple-dose vorapaxar,an oral PAR-1 receptor antagonist,on the single-dose pharmacokinetics and pharmacodynamics of digoxin

Clinical Pharmacology in Drug Development

Volumn 2, Issue 1, 2013, Pages 90-98

  Kosoglou, Teddy ^a   Zhu, Yali ^a   Statkevich, Paul ^a   Xuan, Fengjuan ^a   Schiller, James E ^a   Johnson Levonas, Amy O ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Digoxin; PAR 1; Pharmacodynamics; Pharmacokinetics; SCH 530348; Vorapaxar

Indexed keywords

DIGOXIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ANTAGONIST; VORAPAXAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SINGLE DRUG DOSE; STOMACH DISCOMFORT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 84892489040     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.11     Document Type: Article

References (16)

1. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061-3064.
2. Chintala MVS, Kurowski S, Sabin C, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys [abstract]. Atheroscler Thromb Vasc Biol. 2008;28:e32-e149.
3. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68:249-258.
4. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Eng J Med. 2012;366:20-33.
5. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413.
6. Gheorghiade M, Harinstein ME, Filippatos GS. Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care. 2009;11:83-87.
7. Reuning RH, Geraets DR, Rocci ML, Vlasses PH. Digoxin. General principles of clinical pharmacokinetics. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Wolters Kluwer; 1992; 1-48.
8. Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit. 1991;13:381-401.
9. Williamson KM, Thrasher KA, Fulton KB, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med. 1998;158:2444-2449.
10. Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85:173-181.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
12. Reuning RH, Geraets DR. Digoxin. Applied pharmacokinetics: principles of therapeutics drug monitoring. 2nd ed. Spokane, Wash: Applied Therapeutics Inc; 1986; 570-623.
13. Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39:30-38.
14. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol. 1999; 39:1203-1211.
15. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68:291-300.
16. Reyderman L, Kosoglou T, Tseng J, et al. The effect of food and antacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects [abstract]. Clin Pharmacol Ther. 2009;85: S21.